Table 4.
Life expectancy, breakdown of total discounted expected costs and QALYs, and ICER associated with each treatment strategy.
| Category | Cost ($) | QALYs* | ||||
|---|---|---|---|---|---|---|
| PR48 | BOC/RGT | BOC/PR48 | PR48 | BOC/RGT | BOC/PR48 | |
| Life expectancy | NA | NA | NA | 24.74 | 26.07 | 26.34 |
| Drug† | 19,948 | 52,787 | 69,776 | NA | NA | NA |
| Anemia | 1,716 | 6,875 | 7,480 | −0.01 | −0.02 | −0.02 |
| Monitoring | 1,423 | 1,929 | 2,376 | NA | NA | NA |
| SVR | 0 | 0 | 0 | 2.90 | 7.99 | 9.06 |
| F0–F3 | 7954 | 4560 | 3843 | 7.06 | 4.1 | 3.47 |
| F4 | 5,376 | 2,928 | 2,428 | 2.41 | 1.31 | 1.09 |
| DC | 5,933 | 3,560 | 3,078 | 0.21 | 0.13 | 0.11 |
| HCC | 7,096 | 4,070 | 3,453 | 0.14 | 0.08 | 0.07 |
| Liver transplant | 4,028 | 2,376 | 2,041 | 0.08 | 0.05 | 0.04 |
| Total | 53,474 | 79,085 | 94,475 | 12.79 | 13.64 | 13.8 |
| ICER ($/QALY) | -- | 30,241 | 91,506 | |||
*
QALYs were rounded to 2 decimal places for reporting in the table, but ICERs were estimated using exact QALYs from the model
†
Drug cost includes dual therapy cost for PR48 and triple therapy cost for BOC/RGT and BOC/PR48
PR48= peginterferon-ribavirin regimen; BOC/RGT = Response Guided Therapy; BOC/PR48 peginterferon–ribavirin-boceprevir regimen; DC = decompensated cirrhosis; HCC = hepatocellular carcinoma; QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio.